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Simnumy The aim of the protocol was to evaluate the side-effects induced by repeated tumour-infiltrating
lymphocyte (TIL) infusions in patients with metastatic melanoma (MM). Patients were to receive four TIL
infusions at given intervals: every 3 weeks (two patients), every 2 weeks (3 patients) and weekly (4 patients).
All patients were evaluated and received a total of 34 TIL infusions. The total number of TILs administered
varied from 0.65 to 2.35 x 10" cells. TIL phenotypes were predominantly CD8+ (two patients), CD4+ (4
patients). CD4+ then CD8+ (two patients) or CD56+ (two patient). Autocytotoxicity was only observed for
one culture. Six patients presented at least one WHO grade 3 side-effect: hypotension (5 patients), dyspnoea
(two patients), fever (one patient), fatigue (one patient), chills (two patients), diarrhoea (one patient), agitation
(one patient), locoregional pain (two patients). Hypotension was constantly seen in patients who were given
TILs every week. Two cases of minor pericarditis were recorded. No objective response to treatment was
observed; 1 stable disease occurred in one patient and progression in eight. However, five patients presented a
partial response on a tumour site for 1-4 months. Three patients presented signs of inflammation or softening
at one tumour site. Plasma tumour necrosis factor u (TNF-m) levels were increased 1.2- to 22-fold after TIL
infusion. TILs could be produced in sufficient quantity to perform this study, so repetitive infusions of TIL
became possible on a weekly basis. However, no objective response was observed even when TIL infusions
were performed weekly. An increase in circulating TNF-x was noted after TIL infusion.
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The prognosis of metastatic melanoma is poor with a median
survival of 6-8 months (Balch et al., 1989). Chemotherapy
achieves only 15-25% objective response rates (Balch et al.,
1989). Immunotherapy protocols based either on alpha-inter-
feron or interleukin 2 (IL-2) alone or associated with
lymphokine-activated killer (LAK) cells have not produced
major changes, since the overall objective response rates have
remained at 15-35% and the duration of responses obtained
is usually short (Kirkwood and Ermstoff, 1986; Rosenberg et
al., 1989).
Growing tumour-infiltrating lymphocytes (TILs) in vitro
frequently allows the generation of CD3+ CD8+ cytotoxic T
lymphocytes (CTLs), which may induce a selective lysis of
autologous tumour cells in 30% of patients with melanoma
(Muul et al., 1987; Itoh et al., 1988; Topalian et al., 1989). A
second population of CD3+ CD4+ cells can also be estab-
lished, and these TlLs, have the ability to release or activate
cytokines (Fossati et al., 1988). By using labelled TILs, a
substantial accumulation at the tumour site has been des-
cribed for humans (Fisher et al., 1989). The adoptive transfer
of TILs has proved to be capable of mediating the regression
of lung micrometastases from various tumour types in experi-
mental animal models, and a relationship between the degree
of response and the number of TILs infused has been
reported in experimental systems (Spiess et al., 1987).
The first trial with TILs administered concomitantly with
IL-2 resulted in a 55% response rate in 20 patients with
melanoma (Rosenberg et al., 1988; Topalian et al., 1988);
nevertheless, subsequent studies were unable to show any
significant increase in an objective response rate over treat-
ment with IL-2 alone (Kradin et al., 1989; Dillman et al.,
1991; Hanson et al., 1991; Markowitz et al., 1991).
The toxicity related to TIL infusion has been established in
patients with lung cancer (Kradin et al., 1987) and renal cell
carcinoma (Bukowski et al., 1991). In these instances, TILs
were administered either as a single infusion or as a repeated
infusion with fewer than I x 1010 cells per infusion. The
side-effects observed were minor or mild and limited to fever,
chills, nausea, decrease in vital capacity at respiratory tests.
When TILs were administered together with IL-2, each
infusion generally contained more than 10'0 cells and the
toxicity was mainly related to the high dose of IL-2
(Rosenberg et al., 1988; Topalian et al., 1988; Kradin et al.,
1989; Bukowski et al., 1991; Dillman et al., 1991; Hanson et
al., 1991; Markowitz et al., 1991). The clinical value of TILs
is reflected in their ability to be potentially cytotoxic and to
induce a cooperative immune response. In view of these
characteristics and a possible relationship between response
and the number of TILs infused, we designed a phase I trial
in patients with advanced or metastatic melanoma to study
the tolerance to repeated infusion of TILs at progressively
shorter intervals ranging from 3 weeks to 1 week.
Materials and methods
Inclusion criteria
Patients included in this study were adults (18-71 years) with
a histologically proven metastatic or locally advanced
melanoma at a location which could be easily sampled. In
every case, at least one measurable lesion had to remain after
sampling for in vitro culture. All patients had clear signs of
progressive disease during the last month before inclusion in
the study, an ECOG performance status of 0-2 and an
expected survival time exceeding 3 months. Previous therapy
(chemotherapy, immunotherapy, extensive radiotherapy) had
to have been completed for at least 4 weeks. Patients requir-
ing corticosteroids or immunosuppressive drugs and patients
with evidence of cardiovascular disease (congestive heart
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failure, uncontrolled hypertension, angina pectoris or myo-
cardial infarction) or pulmonary dysfunction were excluded
from the study. Patients with positivity for human immuno-
deficiency virus or hepatitis B surface antigens were also
ineligible. Furthermore, patients with central nervous system
metastases were also excluded from this study, except for
those with a stable clinical course after surgical and/or
radiotherapeutic treatment. In addition, adequate haemato-
poietic and hepatic organ function were necessary, as defined
by: white blood cell count of 2000mmnE3 or higher, platelet
count of 150000mm-3 or higher, serum bilirubin <35pmol
1-1, level of phosphatase alaline <1000 IU 1-', level of
SGOT or SGPT <1201U1-'; creatinine level <150Pmol
1-'.
TILs in culture had to reach at least 10'0 for the first
infusion before the patient could be included in the study.
This protocol was approved by the Ethical Committee of
Fondation Bergonie and by the Consultative Committee for
Protection of People involved in Biomedical Research (CCP-
PRB) of Bordeaux. All the patients had to give written
informed consent to be included in this study.
TIL cultures
Tuowur cell suspension Melanoma tumours were dissected
into 5 mm3 pieces while immersed in RPMI-1640 medium
(Gibco BRL) containing hyaluronidase type V 0.01%,
DNAse type I 0.002%, collagenase type IV 0.1% (Sigma,
France), penicillin and streptomycin.
Free cells from the tumour were washed and immediately
seeded, while tumour pieces were then stirred for 8-18 h at
room temperature. Then, tumour fragments were removed
and the tumour cell suspension centrifuged (400g for 10
min).
The pellet was washed twice and seeded in AIM V culture
medium (Gibco) supplemented with 20% LAK cell super-
natant and 1000Uml-' rIL-2.
Production of LAK cell supernatant Human peripheral
blood mononuclear cells were obtained from leukapheresis
specimens (CRTS, Bordeaux, France). Cells were suspended
in RPMI-1640 medium containing 2% heat-inactivated
human AB serum, penicillin and streptomycin at a cell con-
centration of 1 x 10cellsml.'. Human rIL-2 (Proleukin,
Cetus) was added at 1000 U ml '. Incubation was conducted
for 4-5 days in 75 cm3 flasks (Falcon, Oxnard, CA, USA).
Culture supematants were harvested, pooled, centrifiged and
filtered (0.2pmn) before use in TIL culture.
Culture of twnour-infiltrating lymphocytes This was per-
formed with a modification of the procedure reported by
Topalian et al. (1987). Cell tumour suspensions were diluted
at S xlO5cellsml'- in a culture medium combining 80%
AIMV (Gibco) and 20% LAK cell supernatant without addi-
tional human serum and contng antibiotics (penicillin and
streptomycin), L-glutamine 2 mM (Gibco) and recombinant
human IL-2 at 1000 U ml-' (Proleukin, Cetus). TIL cultures
were distributed into 175 cm3 culture flasks (Falcon) and
were maintained at 3TC in a humidified 5% anrbon dioxide
atmosphere. Once a week, cells were harvested, spun down
and resuspended in fresh medium. At day 15, cells were
placed into 750 cm3 culture bags (Travenol) and then every
week each bag was duplicated in two others supplemented
with fresh medium.
On the day of infusion, all the culture bags (40-80) were
connected together with sterile plastic tubing and the cells
were harvested and washed using a Stericell processor
(Dupont de Nemours).
Chromiwn-release assay of cytotoxicity A 4 h chromium-
release assay (5'Cr) was performed by using as target cells
cryopreserved autologous malignant melanoma tumour cells
obtained while initiating TIL culture. Target cells were
thawed and diluted in RPMI-1640 medium containing 20%
human type AB serum. After washing twice, 200FCi of
radioactive sodium chromate was added to the cells followed
by incubation for 120mim at 37C. Then, the target cells were
washed twice in RPMI-1640 plus 10% AB serum, incubated
at 37C for another 30min, then washed again twice,
counted and resuspended at i0 ml-'. In round-bottom 96-
well plates, 5 x I10 target cells were combined with a varying
number of effector cells. These plates were incubated for 4 h
at 3TC, then the supernatant (100#I) was harvested and
counted in a gamma counter.
Target cells incubated in medium alone or with Triton
were used to determine spontaneous and maximum release of
chromium. All determinations were made in triplicte. The
percentage lysis was calculated by:
Experimental c.p.m. - spontaneous c.p.m.
Maximal c.p.m. - spontaneous c.p.m.
Phenotypic analysis oflymphocytes Lymphocytes were wash-
ed with cold RPMI-1640 containing 5% inactivated fetal calf
serum, and resuspended at a concentration 1 x 106 cells ml-'.
Fluorescein- or phycoerythrin-conjugated monoclonal anti-
bodies (Immunotech, Marseile, France) to human T-lympho-
cyte markers were added to 100jil of cell suspension. The
antibodies routinely used were anti-CD3, anti-CD4, anti-
CD8 and anti-D56. After staining for 60 min at 4C, cells
were washed and fixed with 1/% paraformaldehyde. Fluore-
scence analysis was performed using a FACscan (Becton
Dickinson).
Study design
Patients included in the protocol received four consecutive
TIL infisions. Intervals between each infusion were 3 weeks
for two patients (patients I and 2), 2 weeks for three patients
(patients 3 to 5) and 1 week for four patients (patients 6-9).
In instances where TIL cultures could provide one additional
infusion, the treatment period was extended according to the
level assigned to the patient.
Treatment protocol
TILs were administered i.v. for 15-30nmin through a central
venous catheter. TILs were infused in 200-250 ml bags, and
patients could receive a maximum of 6 x 101" TIL cells. No
IL-2 was added at any time to the infusion bag. Paracetamol
was given when fever occurred. TIL infusion was slowed
down in patients who presented repetitive and severe
chills.
Treatmentprotocolforpatients with diseaseprogression
Patients with progressive disease during TIL therapy received
recombinant IL-2 (Proleukin, Cetus, Emeryvile, CA, USA)
in a continuous infusion at a dose of 18 x 10'6 Um2, added
to the subsequent TIL infusion according to the initial TIL
infusion schedule. IL-2 administration was continued for 5
days for the patients with a treatment interval of 3 or 2
weeks, and for 3 days for those with a treatment interval of I
week. Administration of IL-2 was initiated I h after the
completion of infusion.
Study monitoring
Following infusion, haematological and biochemical para-
meters were assessed five times in the first week and only
weekly thereafter. Echocardiography and respiratory tests
were performed before and 3-5 days after each infusion.
Immunological evaluation included measurement of TNF-x
in the plasma and phenotyping of peripheral mononuclear
cells. TNF-z was assessd using an enzyme-linked
immunosorbant assay (Immunotech, Marseille, France). The
sensitivity was 0.5 pgml-'.Response criteria
Before each TIL infusion, patients were assessd for res-
ponse. Complete response (CR) was defined as the complete
disappearance of all clinically detectable disease for at least 4
weeks. A partial response (PR) was defined as a 50% or
greater decrease in the products of perpendicular diameters
for all measurable lesions for at least 4 weeks, without new
lesions. The duration of CR or PR was calulated from the
first day of treatment. Stable disease (SD) was defined as a
less than 25% incrase or a less than 50% decrease in
tumour size, and progressive diseaw (PD) as an incrase of
greater than 25% in measurable ksions or the appearance of
new lesions. Patients with CR, PR or SD, as well as those
with a response on at least one tumour site, were to be
further evaluated every 4-6 weeks during the first 6 months
after treatment and every 2-3 months thereafter. Survival
duration was evaluated from the first day of treatment to
date of death.
Statistics
Data are presented as median for age, TIL culture period,
number of cells and total TILs infused.
Redls
Patients
From July 1991 to April 1993, 11 patients were considered
for entry into the protocoL but in two cases TIL production
could not be expanded to 1010 cells. Nine patients were
included in the protocol and all patients were evaluable for
toxicity and response. There were five males and four
females, with a median age of46 years (range 35-68). ECOG
performance status was 0 for six and 1 for three patients.
Three patients had previously received immunotherapy
alpha-interferon alone (two patients) or an association of
dacarbazine, subcutaneous interleukin 2 and alpha-interferon
(Avril et al., 1993). Two patients had previously only
received chemotherapy. At the time of enrolment, metastatic
involvement included superficial or deep lymph nodes (seven
patients), soft-tissue or subcutaneous lesions (six patients),
lung (four patients), liver (three patients) and peritoneal (one
patient) involvement.
TIL growth (Table I)
TILs were sampled from soft tissue (five patients), lymph
nodes (three patients) and lung (one patient). Subcutaneous
ksions from one patient were resected during the study to
provide a complementary source of TIL. In all nine patients
considered, TIL cultures reached 1010 cells to be used for the
first infusion. The time between setting up TIL cultures and
the first infusion, providing 2-7 x 10'° cls for infusion,
ranged from 50-90 days (median: 60 days).
-nob TLkk. in mdubc md
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Phenotypic analysis andautocytotoxicity (Table I)
Staining for CD8+/CD4+ was performed prior to each
infusion of TILs and in four cultures showed a CD4+/CD8+
ratio higher than 1, and in two cultures a CD4+/CD8+ ratio
lower than 1. Eighty-one and 121 days after set-up, two
cultures changed their phenotype from a majority of CD4+
cells (90% and 95% respectively) to mostly CD8+ T cells
(92% and 48% respectively). CD56+ cells grew on one cul-
ture, but could be maintained only for two infusions. In one
patient (patient 1), a subcutaneous lesion was surgically
resected after 1 month of treatment and a single infusion of
TILs. This lesion had presented signs of inflammation and a
decrease in size of 25-50%. Although the culture from the
original lesion provided a TIL population which was pre-
dominantly CD4+ (90-98% for three infiLsions), this sub-
cutaneous lesion yielded a cell population which was pre-
dominantly CD8+ TILs. Autocytotoxcity was evaluated in
eight cultures and was not tested for the population of
CD56+. Autocytotoxicity was > 10% for one culture, associ-
ated with a CD8+ phenotype.
Treatment
A total of 34 infusions of TILs were given to the nine
patients. Seven patients received the complete series of four
infusions and two of these patients received an additional
fifth infusion. In two patients, only two infusions were given:
for one patient, the culture grew only for CD56+ cells; for
the other patient, the treatment with TIL + IL-2 led to life-
threatening toxicity (Ravaud et al., 1992). The number of
TILs per infusion varied from 0.8 to 7 x 10' cells (median
3 x 10's cells). Total TILs administered varied from 0.65 to
2.35 x 101" cells (median 1.05 x 10"1 cells).
Toxicity
Toxicties encountered were evaluated according to the WHO
grading system. Grade 3 hypotension was a decrease of
30-40mmHg in systolic pressure or the need for i.v. fluid
therapy. The side-effects with TILs alone are presented in
Table H and included fever (grade 3, one patient, grade 2,
seven patients), chills (six patients) and mild to severe
asthenia (two patits). Fever, asthenia and chills usualy
occurred immiatel with the first infusion. Digestive
disorders were reported by three patients with vomiting (up
to grade 2) and diarrhoea (up to grade 3). Four patients
complained of headache. One patient had a severe episode of
anxiety. None of these side-effects were correlated with the
treatment intervals.
Six patients had hypotension, of whom five had grade 3
hypotension. All patents treated every week had at least
once a grade 3 hypotension. Hypotension could arise for the
first time after any of the infusions.
A minor asymptomatic pericardiac effusion was recorded
during the treatment of two patients and was not correlated
to the course of disease. Two patients had grade 3 res-
Table I Characteristics ofTIL cultures
Days in
Patient culture (for First infusion Second infusion Thirdinfusion Fourth infusion Ffth infusion
no. Tisue resected firstinfsion) a b c a b c a b c a b c a b c
Subcutaneous 60 6 94/10 0 3 94/6 ND 1 98/2 ND
7 40/54 0
Lymph node 47 5 18/82 0
2 Lymph node 56 5 0/100 17 5 0/100 15
3 Lymph node 61 4.25 72/19 ND 2.5 70/30 ND 2 42/57 ND 3 72/20 ND 1.2 25/75 0
4 Lung 50 4.3 100/0 ND 4.1 100/0 ND I 100/0 ND 1 100/0 ND
5 Subcutaneous 56 6.5 CD56' ND 1 CD56+ ND
6 Subcutaneous 58 7 95/4 ND 6 95/4 0 5 74/21 ND 6 46/48 0
7 Subcutaneous 60 6 97/1 0 4 97/1 ND 6 100/0 ND 2 100/0 0
8 Subcutaneous 90 3 97/3 0 3 100/0 ND 3 100/0 ND 2 100/0 0
9 Lymph node 70 2 28/67 0 2 24/72 ND 2 10/87 ND 1 14/80 0
a, cedls infused ( x 10-1'); b, CD4+/CD8+ (%); c, autocytotoxicity (%). ND, not determined.Rqoodbp TL n " in.d c mdnm
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Table H Toxicities ofrepeated TIL infusions by WHO grade (1-4) and by frequency ofTIL infusions*.
Thenumberofpatientsatthemaximumtoxicityencountered isshown,withthenumberofinfusionsgivenin
parentheses
1 2 3 4
a b c a b c a b c a b c
Fever 2(5) 1(6) 4(13) 1(1)
Asthenia 1(4) 1(1)
Chills (1) 1(2) 2(9) 1(5) 2(4)
Headache 1(3) 3(5)
Nausea/vomiting (2) 1(2) 2(3)
I)iarrhoea 1(2) 1(1)







tumour site 1(1) 1(2) 1(1)
Locoregional pain 1(5) 1(2)
*a, TIL infusion every 3 weeks; b, TIL infusion every 2 weeks; c, TIL infusion every week.
Table m Plasma TNF-a concentration (pgml') (4-7 days after
infusion)
Patint Pretreat- Infusion no.
no. mieat 1 2 3 4 5
1 0.5 4.7 4.2 11 aND a51.5
2 10.1 21.8 '250
3 4.2 0.5 3.4 ND 6.9
4 3 4.2 7.3 7.3 a41.7 a28
5b 7.3 4.7 ND
6 8.7 4.3 4.3 10.1 10.6
7 6 8.7 5.1 13.4 ND
8 10.1 11 11.5 12.5 14.4
9 3.8 13.9 10.1 17.8 3.4
ND, not done. aAfter TILs + IL-2. bC56+ population.
piratory distress. One patient suffered from a mild coagulo-
pathy following each of the four infusions by 4-6 h; he
developed a thrombocytopenia associated with a prolonga-
tion ofprothrombin time (+ 30 to 70%) and a drop in factor
VII + X (= 19-30%). D-dimers were negative. No infectious
complications occurred. Finally, no sde-effects led to inter-
ruption of the treatment.
The frequency and severity of side-effects were correlated
neither with the number of cells infused (mean cells infused
was 3.6 x 1010) nor with phenotype.
Response to treatment
No objective response could be achieved in any of the nine
patients with metastatic melanoma treated with TILs. There
was one case of stable disease (3 months) and eight of
progressive diseas. Nevertheless, five patients presented a
tansient response on at least one of the tumour sites after
infusion of TILs alone. Two patients had a partial response
at the site of lymph nodes which lasted for 4 months and 1
month. Another partial response of 1 month duration was
noted in a patient with a subcutaneous lesion. One patient
presented an increase in the size of a liver metastasis follow-
ing the first infusion; however, after the second TIL infiusion
a partial response occurred for 1 month. Another patients
showed a minor decrease for 1 month (25-50%) in a sub-
cutaneous lesion before it was resected for a second culture
of TILs. Partial responses for at least one lesion were seen in
one patient treated every 3 weeks, in two patients treated
every 2 weeks and in one patient treated weekly. Inflam-
mation or softening of at least one tumour lesion was
achieved in three patients after the first or second infusion.
Two patients presented mild pain in the leg where tumoral
lesions were located; however, signs of inflammation of the
local tumour were not apparent.
The addition of IL-2 to the treatment with TIL in these
three patients who experienced a progression with TIL alone
did not result in an objective response.
At the final analysis of this phase I trial, five patients had
died from melanoma, 2-15 months after therapy, while four
patients were alive with evidence of disease 8-16 months
after the first infusion of TILs.
Imrmmological evahuation
Assessment of plasmatic TNF-a, 4-7 days after each
infusion, showed a maximum of a 1.2- to 22-fold increase
following TIL therapy (Table III). All patients but one had
the maximum level of TNF-a after the last infusion of
TIL.
No change was observed in CD45RA, CD45RO, CD25,
CD28, CD29W of peripheral blood cells before and after
each TILs infusion.
Previous studies of treatment with TILs alone have reported
only limited toxicities (Kradin et al., 1987; Bukowski et al.,
1991; Marincola et al., 1993), which did not include grade 3
side-effects. In our study, WHO grade 3 toxic events occurred
in six patients after 13/34 infusions. Modifications in arterial
blood pres and heart rate were encountered more often
in our study than in the NCI trial (21), in which no grade 3
hypotension was seen. In particular, hypotension and
accelerated heart rate were more frequent when TILs were
infused once a week. Following TIL therapy, a minor peri-
carditis was detected by a systematic echocardiography after
the last infusion in two patients. In each case, the extent of
pericarditis was limited and there were no clinical signs.
Compared with other studies (Kradin et al., 1987; Marin-
cola et al., 1993), the observed increase in frequency and
severity of these side-effects could be due to the larger
number of cells infused (Kradin et al., 1987) and to a longer
period of follow-up after TIL infusions (Marincola et al.,
1993). In our study, TILs were administered over a shorter
period of time (15-30min) compared, for example, with
30-60 min infusion time in the NCI study. Considering TIL
infusions without subsequent IL-2 treatment (29/34
infusions), the mean time of maximum changes in arterial
blood pressure and heart rate occurred after 4.5 and 3.8 h
respectively. Repeated infusion of TILs alone did not result
in an objective response, although five patients presented a
sign nt decrease in tumour volume in at least one tumour
site. This response could be evaluated in three patients with
subcutaneous and lymph node lesions by signs of mild
inflammation or softening of tumour prior to decrease inRepea. TL iuvsion in metastatic melanoma
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size. In one patient with multiple subcutaneous lesions
localised in one leg. there was also an objective response in
conjunction with local pain without signs of inflammation.
Therefore. clinical inflammation or softening of the tumour
seemed to be associated with a clinical response of the sub-
cutaneous melanoma. Histological changes with lymphocytic
infiltrates, tumour necrosis and lymphocytic vasculitis have
been reported in patients with subcutaneous metastases of
lung carcinoma showing an objective response to immuno-
therapy with TILs and IL-2 (Kradin et al., 1989). More
recently. it was reported that the percentage of tumour
necrosis present after TIL administration combined with IL-2
was significantly higher in responder than in non-responder
patients with melanoma. in comparison with the pre-TIL
baseline value (Cole et al.. 1994).
The benefit of surgical excision after a previous exposure
to TILs to produce more autocytotoxic CD8+ T cells in a
new TIL culture cannot be assumed from the single patient
case in this study. Nevertheless, there was a switch from a
predominant CD4+ phenotype (94%) to a CD8+ population:
however, no autocytotoxicity could be detected.
Whether or not TILs given to patients are able to induce
cytokine secretion and thus activate immunocompetent cells
remains unclear. An increase in plasmatic TNF-a could be
detected after 4-7 days following TIL infusion. TNF-a is
known to have a short half-life (Beutler et al., 1986) and is
not usually produced by unstimulated TIL in vitro (Schwart-
zentruber et al., 1991: Hom et al., 1993). However, recent
reports have described the release of cytokines, including
TNF-a, by in vitro co-culture of TILs with either autologous
tumour stimulation (Schwartzentruber et al., 1991) or, more
recently, with HLA-matched melanoma tumour cells (Hom
et al., 1993). Secretion of TNF-a after stimulation in vitro
followed a lag period and was maximal within the first 24 h
(Schwartzentruber et al., 1991). In this study, TILs given in
vivo, and in the absence of exogenous IL-2, were able to
induce levels of TNF-a detectable in the serum. At this point,
we can only speculate on the nature of this TNF-a increment.
Increased levels of TNF-x could be a non-specific pheno-
menon following infusion of a large number of immune cells;
or alternatively, it could reflect a more specific interaction
between immune T cells and malignant melanoma
antigens.
Following repeated TIL infusions, we did not find any
phenotypic changes in the peripheral blood cells. The lack of
such changes may suggest that there was no activation of the
cells of the immune system in this study, just as reported in a
previous report for natural killer. LAK and T cells
(CD45RO, CDW29) following single TIL infusion (Bukowski
et al., 1991).
After progression of disease under TIL treatment, the three
patients infused together with IL-2 still did not present any
objective response. This finding is in contrast to some
(Rosenberg et al., 1988; Topalian et al.. 1988) but not other
(Dorval et al., 1992) reports claiming that the combination of
TIL + IL-2 can reinduce an objective response after failure of
IL-2 alone.
In conclusion, repeated infusions of more than 1010 TILs
are feasible, without severe side-effects. However, WHO
grade 3 side-effects were more frequently observed in this
study than in previous trials. No objective tumour response
was observed, although some biological changes were noted,
including an increase in plasmatic levels of TNF-a.
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